Publications

Export 6 results:
Author Title [ Type(Asc)] Year
Filters: Author is Meyer, Pierre-François  [Clear All Filters]
Journal Article
Köbe T, Binette APichet, Vogel JW, Meyer P-F, Breitner JCS, Poirier J, Villeneuve S.  2021.  Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer's disease: Vascular risk factors and functional connectivity changes.. Neuroimage. 231:117832.
Meyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS.  2019.  No apparent effect of naproxen on CSF markers of innate immune activation.. Ann Clin Transl Neurol. 6(6):1127-1133.
Meyer P-F, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan M-É, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner JCS.  2019.  INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease.. Neurology. 92(18):e2070-e2080.
Meyer P-F, Savard M, Poirier J, Morgan D, Breitner JCS.  2019.  Hypothesis: cerebrospinal fluid protein markers suggest a pathway toward symptomatic resilience to AD pathology.. Alzheimers Dement. 15(9):1160-1171.
Meyer P-F, Savard M, Poirier J, Labonte A, Rosa-Neto P, Weitz TM, Town T, Breitner JCS.  2018.  Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer's Disease Pathogenesis.. J Alzheimers Dis. 63(2):577-590.
Meyer P-F, McSweeney M, Gonneaud J, Villeneuve S.  2019.  AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention.. Prog Mol Biol Transl Sci. 165:63-106.